RAPPORT THERAPEUTICS INC (RAPP) Stock News

USA - Nasdaq - NASDAQ:RAPP - US75383L1026 - Common Stock

28.7 USD

+0.94 (+3.39%)

Last: 12/4/2025, 8:00:02 PM

28.7 USD

0 (0%)

After Hours: 12/4/2025, 8:00:02 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

RAPP Latest News, Press Relases and Analysis

All

Press Releases

7 days ago - By: Zacks Investment Research

Wall Street Analysts See a 74.99% Upside in Rapport Therapeutics, Inc. (RAPP): Can the Stock Really Move This High?

10 days ago - By: Rapport Therapeutics, Inc.

Rapport Therapeutics to Present New Phase 2a Data Analysis Further Characterizing RAP-219 in Focal Onset Seizures at 2025 American Epilepsy Society Annual Meeting

16 days ago - By: Benzinga - Mentions: EXTR NSIT PSN RIOT

This Extreme Networks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

23 days ago - By: Zacks Investment Research

Wall Street Analysts Think Rapport Therapeutics, Inc. (RAPP) Could Surge 104.47%: Read This Before Placing a Bet

3 months ago - By: Stocktwits - Mentions: IWMW UWM

News Image

Rapport Therapeutics Stock Rockets 204% Pre-Market To Head Toward All-Time Highs – Here’s What Happened

4 months ago - By: The Motley Fool

Rapport (RAPP) Q2 Net Loss Widens 47%

a month ago - By: Rapport Therapeutics, Inc.

Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update

a month ago - By: Rapport Therapeutics, Inc.

Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update

a month ago - By: Rapport Therapeutics, Inc.

Rapport Therapeutics to Participate in Upcoming Investor Conferences

3 months ago - By: Rapport Therapeutics, Inc.

Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

3 months ago - By: Rapport Therapeutics, Inc.

Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

3 months ago - By: Benzinga - Mentions: ACTU CAMP GNPX PMVP ...

12 Health Care Stocks Moving In Wednesday's Intraday Session

3 months ago - By: Rapport Therapeutics, Inc.

Rapport Announces Pricing of Public Offering of Common Stock

3 months ago - By: Rapport Therapeutics, Inc.

Rapport Announces Pricing of Public Offering of Common Stock

3 months ago - By: Rapport Therapeutics, Inc.

Rapport Announces Proposed Public Offering of Common Stock

3 months ago - By: Rapport Therapeutics, Inc.

Rapport Announces Proposed Public Offering of Common Stock

3 months ago - By: Investor's Business Daily - Mentions: PFE

Rapport Catapults Almost 200% After Succeeding In Hard-To-Treat Seizures

3 months ago - By: Rapport Therapeutics, Inc.

Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures

3 months ago - By: Rapport Therapeutics, Inc.

Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures

3 months ago - By: Rapport Therapeutics, Inc.

Rapport Therapeutics to Announce Topline Results for RAP-219 Phase 2a Trial in Focal Onset Seizures on Monday, September 8, 2025

3 months ago - By: Rapport Therapeutics, Inc.

Rapport Therapeutics to Announce Topline Results for RAP-219 Phase 2a Trial in Focal Onset Seizures on Monday, September 8, 2025

4 months ago - By: Rapport Therapeutics, Inc.

Rapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business Update

4 months ago - By: Rapport Therapeutics, Inc.

Rapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business Update